Phase I Trial of Anti–Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration

Ophthalmology Retina

Volumn 1, Issue 6, 2017, Pages 474-485

  Chakravarthy, Usha ^a   Bailey, Clare ^b   Brown, David ^c   Campochiaro, Peter ^d   Chittum, Mark ^e   Csaky, Karl ^f   Tufail, Adnan ^g   Yates, Paul ^h   Cech, Patrick ⁱ   Giraudon, Mylene ⁱ   Delmar, Paul ⁱ   Szczesny, Piotr ⁱ   Sahni, Jayashree ⁱ   Boulay, Anne ⁱ   Nagel, Sandra ⁱ   Fürst Recktenwald, Sabine ⁱ   Schwab, Dietmar ⁱ  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b BRISTOL EYE HOSPITAL   (United Kingdom)

^c RETINA CONSULTANTS OF HOUSTON   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Retina Consultants of Southern Colorado PC   (United States)

^f TEXAS RETINA ASSOCIATES   (United States)

^g MOORFIELDS EYE HOSPITAL   (United Kingdom)

^h UNIVERSITY OF VIRGINIA   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN 2; BEVACIZUMAB; CLOPIDOGREL; RANIBIZUMAB; RG 7716; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN RECEPTOR;

ADULT; AGED; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; ATRIAL FIBRILLATION; BEST CORRECTED VISUAL ACUITY; BLEPHARITIS; BLURRED VISION; BREAST DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVITIS; CONNECTIVE TISSUE DISEASE; CONTRAST SENSITIVITY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; EVALUATION AND FOLLOW UP; EYE EXAMINATION; EYE INFLAMMATION; EYE PAIN; EYE SWELLING; FEMALE; FLUORESCENCE ANGIOGRAPHY; FREQUENCY ANALYSIS; GASTROINTESTINAL DISEASE; HUMAN; HYPEREMIA; HYPERTENSION; INDOCYANINE GREEN ANGIOGRAPHY; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOCYCLITIS; IRIS PIGMENT EPITHELIUM; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHOTODYNAMICS; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINA HEMORRHAGE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; SYSTOLIC BLOOD PRESSURE; UVEITIS; VASCULAR DISEASE; VERY ELDERLY; WET MACULAR DEGENERATION; YOUNG ADULT;

EID: 85038421197     PISSN: None     EISSN: 24686530     Source Type: Journal    
DOI: 10.1016/j.oret.2017.03.003     Document Type: Article

References (38)

1. Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, Maguire, M.G., Martin, D.F., et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 123 (2016), 1751–1761.
2. Rofagha, S., Bhisitkul, R.B., Boyer, D.S., et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120 (2013), 2292–2299.
3. Maisonpierre, P.C., Suri, C., Jones, P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997), 55–60.
4. Yancopoulos, G.D., Davis, S., Gale, N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000), 242–248.
5. Gavard, J., Patel, V., Gutkind, J.S., Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 14 (2008), 25–36.
6. Nambu, H., Nambu, R., Oshima, Y., et al. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 11 (2004), 865–873.
7. Nambu, H., Umeda, N., Kachi, S., et al. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J Cell Physiol 204 (2005), 227–235.
8. Benest, A.V., Kruse, K., Savant, S., et al. Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One, 8, 2013, e70459.
9. Otani, A., Takagi, H., Oh, H., et al. Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40 (1999), 1912–1920.
10. Regula, J.T., Lundh von Leithner, P., Foxton, R., et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8 (2016), 1265–1288.
11. Gale, N.W., Thurston, G., Hackett, S.F., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 3 (2002), 411–423.
12. Hackett, S.F., Ozaki, H., Strauss, R.W., et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 184 (2000), 275–284.
13. Hackett, S.F., Wiegand, S., Yancopoulos, G., Campochiaro, P.A., Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol 192 (2002), 182–187.
14. Oshima, Y., Oshima, S., Nambu, H., et al. Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive. FASEB J 19 (2005), 963–965.
15. Schaefer, W., Regula, J.T., Bahner, M., et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 108 (2011), 11187–11192.
16. Iwata, D., Lundh von Leithner, P., Ng, Y.S.E., et al. Anti-VEGF/Ang2 bi-specific antibody ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci, 55, 2014, 2354.
17. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985), 1796–1806.
18. Avery, R.L., Castellarin, A.A., Steinle, N.C., et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98 (2014), 1636–1641.
19. Abraham, P., Yue, H., Wilson, L., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150 (2010), 315–324.e1.
20. Brown, D.M., Kaiser, P.K., Michels, M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1432–1444.
21. Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
22. Ho, A.C., Busbee, B.G., Regillo, C.D., et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 121 (2014), 2181–2192.
23. Schmidt-Erfurth, U., Kaiser, P.K., Korobelnik, J.F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121 (2014), 193–201.
24. Glaser, K.B., Li, J., Marcotte, P.A., et al. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther 343 (2012), 617–627.
25. Stewart, M., Inhibiting platelet derived growth factor: the next step in the treatment of exudative age-related macular degeneration [editorial]. J Clin Exp Ophthalmol, 3, 2012, e109.
26. Campochiaro, P.A., Sophie, R., Tolentino, M., et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology 122 (2015), 545–554.
27. Toth, L.A., Stevenson, M., Chakravarthy, U., Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: outcomes in eyes with poor initial vision. Retina 35 (2015), 1957–1963.
28. Ying, G.S., Kim, B.J., Maguire, M.G., et al. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 132 (2014), 915–921.
29. Jaffe, G.J., Ciulla, T.A., Ciardella, A.P., et al. Dual antagonism of PDGF and VEGF in neovascular age-related macular degeneration: a phase IIb, multicenter, randomized controlled trial. Ophthalmology 124 (2017), 224–234.
30. Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista in Wet Age-Related Macular Degeneration [press release]. December 12, 2016. Available at: http://investors.ophthotech.com/releases.cfm. Accessed January 13, 2017.
31. Regeneron announces Phase 2 study of aflibercept co-formulated with rinucumab (anti-PDGFR-beta) shows no benefit over aflibercept alone in neovascular age-related macular degeneration [press release]. September 30, 2016. Available at: http://investor.regeneron.com/releasedetail.cfm?releaseid=991601. Accessed January 19, 2017.
32. Thomson, B.R., Heinen, S., Jeansson, M., et al. A lymphatic defect causes ocular hypertension and glaucoma in mice. J Clin Invest 124 (2014), 4320–4324.
33. Campochiaro, P.A., Khanani, A., Singer, M., et al. Enhanced benefit in diabetic macular edema from AKB-9778 Tie2 activation combined with vascular endothelial growth factor suppression. Ophthalmology 123 (2016), 1722–1730.
34. Chakravarthy, U., Harding, S.P., Rogers, C.A., et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382 (2013), 1258–1267.
35. Avery, R.L., What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?. Br J Ophthalmol 98:Suppl 1 (2014), i7–i10.
36. Brown, D.M., Chen, E., Mariani, A., Major, J.C. Jr., Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration—primary end point. Ophthalmology 120 (2013), 349–354.
37. Wykoff, C.C., Brown, D.M., Chen, E., et al. SAVE (Super-dose Anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina 44 (2013), 121–126.
38. Busbee, B.G., Ho, A.C., Brown, D.M., et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120 (2013), 1046–1056.